Special items: Ovarian Cancer and Us blog best viewed in Firefox

Friday, August 13, 2010

Expert Opinion on Investigational Drugs - Summary: Histone deacetylase (HDAC) inhibitors

Take home message: There are extensive preclinical studies with transformed cells in culture and tumor-bearing animal models, as well as limited clinical studies reported to date, which indicate that HDAC inhibitors will be most useful when used in combination with cytotoxic or other targeted anticancer agents.

No comments:

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.